Fortress Biotech, Inc. (FBIOP)
- Previous Close
13.44 - Open
13.50 - Bid --
- Ask --
- Day's Range
13.50 - 14.15 - 52 Week Range
6.40 - 18.91 - Volume
4,552 - Avg. Volume
12,603 - Market Cap (intraday)
74.184M - Beta (5Y Monthly) 1.53
- PE Ratio (TTM)
-- - EPS (TTM)
-0.86 - Earnings Date --
- Forward Dividend & Yield 2.34 (17.62%)
- Ex-Dividend Date Apr 12, 2024
- 1y Target Est
--
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
www.fortressbiotech.comRecent News: FBIOP
Performance Overview: FBIOP
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FBIOP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FBIOP
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-71.75%
Return on Assets (ttm)
-37.68%
Return on Equity (ttm)
-597.36%
Revenue (ttm)
84.51M
Net Income Avi to Common (ttm)
-68.67M
Diluted EPS (ttm)
-0.86
Balance Sheet and Cash Flow
Total Cash (mrq)
80.93M
Total Debt/Equity (mrq)
5,582.36%
Levered Free Cash Flow (ttm)
-100.12M
Company Insights: FBIOP
FBIOP does not have Company Insights